On November 3, 2022 Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, reported upcoming presentations for bezuclastinib at the 64th Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper) being held in New Orleans, LA from December 10-13, 2022 (Press release, Cogent Biosciences, NOV 3, 2022, View Source [SID1234622927]). The company will also host a virtual investor event on December 12 that will be accessible via conference call and webcast, with full details to be made available closer to the date.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral presentation details:

Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM)